Immunological properties of engineered nanomaterials

Nature Nanotechnology

Volumn 2, Issue 8, 2007, Pages 469-478

  Dobrovolskaia, Marina A ^a   McNeil, Scott E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED DRUG DELIVERY; IMMUNE SYSTEM; MEDICAL APPLICATIONS; NANOPARTICLES; NANOSTRUCTURED MATERIALS; SURFACE CHEMISTRY; TARGETED DRUG DELIVERY;

BIOMEDICAL APPLICATIONS; DIFFERENT STAGES; ENGINEERED NANOMATERIALS; HARMONIZED STANDARDS; IMMUNE RESPONSE; IMMUNOLOGICAL PROPERTIES; IMMUNOTOXICITY; RECENT RESEARCHES;

NANOMETALS;

BIOVANT; CALCIUM PHOSPHATE; CYCLODEXTRIN; DENDRIMER; DOXORUBICIN; FULLERENE DERIVATIVE; GOLD; IBUPROFEN LYSINE; INFLIXIMAB; LIPOSOME; NANOMATERIAL; NANOPARTICLE; NANOSHELL; NEOPROFEN; PACLITAXEL; POLYAMIDOAMINE; QUANTUM DOT; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HUMAN INSULIN; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; VIVAGEL;

ANTIGENICITY; AUTOIMMUNE DISEASE; BLOOD CLOTTING TIME; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CYTOTOXICITY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG HYPERSENSITIVITY; ENDOCYTOSIS; ERYTHROCYTE APLASIA; HEAD AND NECK CANCER; HEMOLYSIS; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOTOXICITY; INFECTION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KAPOSI SARCOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MYCOSIS; NONHUMAN; OVARY CANCER; PARTICLE SIZE; PATENT DUCTUS ARTERIOSUS; PINOCYTOSIS; PRIORITY JOURNAL; REVIEW; SKIN ALLERGY; T CELL LYMPHOMA; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 34547690726     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/nnano.2007.223     Document Type: Review

References (108)

1. Powers, M. Nanomedicine and nano device pipeline surges 68%. NanoBiotech News 1-69 (4 January 2006).
2. Note for guidance on repeated-dose toxicity (Committee for Proprietary Medicinal Products, London, 2000).
3. Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals (FDA/CBER/CDER, 1997).
4. Developing Medical Imaging Drug and Biological Products. Part1: Conducting Safety Assessments (FDA/CBER/CDER, 2004).
5. Immunotoxicity Studies for Human Pharmaceuticals (FDA/CDER, 2006).
6. Immunotoxicology Evaluation of Investigational New Drugs (FDA/CDER, 2002).
7. Immunotoxicity Testing Guidance (FDA/CDRH, 1999).
8. Leu, D. et al. Distribution and elimination of coated polymethyl [2-14C]methacrylate nanoparticles after intravenous injection in rats. J. Pharm. Sci. 73, 1433-1437 (1984).
9. Gref, R. et al. Biodegradable long-circulating polymeric nanospheres. Science 263, 1600-1603 (1994).
10. Goppert, T. M. & Muller, R. H. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J. Drug Target. 13, 179-187 (2005).
11. McNeil, S. E. Nanotechnology for the biologist. J. Leukoc. Biol. 78, 585-594 (2005).
12. Standard Terminology Relating to Nanotechnology E 2456-06 (ASTM International, 2006).
13. Alivisatos, A. P., Gu, W. & Larabell, C. Quantum dots as cellular probes. Annu. Rev. Biomed. Eng. 7, 55-76 (2005).
14. Bala, I., Hariharan, S. & Kumar, M. N. PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst. 21, 387-422 (2004).
15. Bulte, J. W. & Kraitchman, D. L. Monitoring cell therapy using iron oxide MR contrast agents. Curr. Pharm. Biotechnol. 5, 567-584 (2004).
16. Fiorito, S. et al. Toxicity and biocompatibility of carbon nanoparticles. J. Nanosci. Nanotechnol. 6, 591-599 (2006).
17. Gupta, A. K. & Gupta, M. Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials 26, 1565-1573 (2005).
18. Xu, Y. & Du, Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int. J. Pharm. 250, 215-226 (2003).
19. Gessner, A., Lieske, A., Paulke, B. & Muller, R. Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur. J. Pharm. Biopharm. 54, 165-170 (2002).
20. Gessner, A., Lieske, A., Paulke, B. R. & Muller, R. H. Functional groups on polystyrene model nanoparticles: influence on protein adsorption. J. Biomed. Mater. Res. A 65, 319-326 (2003).
21. Gessner, A. et al. Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int. J. Pharm. 196, 245-249 (2000).
22. Luck, M. et al. Plasma protein adsorption on biodegradable microspheres consisting of poly(D,L-lactide-co-glycolide), poly(L-lactide) or ABA triblock copolymers containing poly(oxyethylene). Influence of production method and polymer composition. J. Control. Release 55, 107-120 (1998).
23. Goppert, T. M. & Muller, R. H. Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN). Eur. J. Pharm. Biopharm. 60, 361-372 (2005).
24. Luck, M. et al. Identification of plasma proteins facilitated by enrichment on particulate surfaces: analysis by two-dimensional electrophoresis and N-terminal microsequencing. Electrophoresis 18, 2961-2967 (1997).
25. Diederichs, J. E. Plasma protein adsorption patterns on liposomes: establishment of analytical procedure. Electrophoresis 17, 607-611 (1996).
26. Gessner, A., Paulke, B. R., Muller, R. H. & Goppert, T. M. Protein rejecting properties of PEG-grafted nanoparticles: influence of PEG-chain length and surface density evaluated by two-dimensional electrophoresis and bicinchoninic acid (BCA)-proteinassay. Pharmazie 61, 293-297 (2006).
27. Gref, R. et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloid. Surf. B 18, 301-313 (2000).
28. Peracchia, M. T. et al. Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials 20, 1269-1275 (1999).
29. Salvador-Morales, C. et al. Complement activation and protein adsorption by carbon nanotubes. Mol. Immunol. 43, 193-201 (2006).
30. Thode, K. et al. Determination of plasma protein adsorption on magnetic iron oxides: sample preparation. Pharm. Res. 14, 905-910 (1997).
31. Luck, M. et al. Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J. Biomed. Mater. Res. 39, 478-485 (1998).
32. Balakrishnan, B., Kumar, D. S., Yoshida, Y. & Jayakrishnan, A. Chemical modification of poly(vinyl chloride) resin using poly(ethylene glycol) to improve blood compatibility. Biomaterials 26, 3495-3502 (2005).
33. Oyewumi, M. O. et al. Comparison of cell uptake, biodistribution and tumor retention of folatecoated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J. Control. Release 95, 613-626 (2004).
34. Koziara, J. M. et al. Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm. Res. 22, 1821-1828 (2005).
35. Wang, J. et al. Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumor-bearing mice. Biochem. Pharmacol. 71, 872-881 (2006).
36. Chamberlain, P. & Mire-Sluis, A. R. An overview of scientific and regulatory issues for the immunogenicity of biological products. Dev. Biol. 112, 3-11 (2003).
37. Swanson, S. J., Ferbas, J., Mayeux, P. & Casadevall, N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin. Pract. 96, c88-c95 (2004).
38. Kivisakk, P., Alm, G. V., Fredrikson, S. & Link, H. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur. J. Neurol. 7, 27-34 (2000).
39. Roberts, J. C., Bhalgat, M. K. & Zera, R. T. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J. Biomed. Mater. Res. 30, 53-65 (1996).
40. Tomii, A. & Masugi, F. Production of anti-platelet-activating factor antibodies by the use of colloidal gold as carrier. Jpn. J. Med. Sci. Biol. 44, 75-80 (1991).
41. Kreuter, J. Nanoparticles as adjuvants for vaccines. Pharm. Biotechnol. 6, 463-472 (1995).
42. Chen, B. X. et al. Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics. Proc. Natl Acad. Sci. USA 95, 10809-10813 (1998).
43. Braden, B. C. et al. X-ray crystal structure of an anti-Buckminsterfullerene antibody fab fragment: biomolecular recognition of C(60). Proc. Natl. Acad. Sci. U. S. A. 97, 12193-12197 (2000).
44. Masalova, O. V. et al. Immunostimulating effect of water-soluble fullerene derivatives - perspective adjuvants for a new generation of vaccine. Dokl. Akad. Nauk 369, 411-413 (1999).
45. Andreev, S. M. et al. Immunogenic and allergenic properties of fulleren conjugates with aminoacids and proteins. Dokl. Biochem. 370, 4-7 (2000).
46. Stieneker, F., Kreuter, J. & Lower, J. High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines. AIDS 5, 431-435 (1991).
47. Castignolles, N. et al. A new family of carriers (biovectors) enhances the immunogenicity of rabies antigens. Vaccine 14, 1353-1360 (1996).
48. Rajananthanan, P., Attard, G. S., Sheikh, N. A. & Morrow, W. J. Evaluation of novel aggregate structures as adjuvants: composition, toxicity studies and humoral responses. Vaccine 17, 715-730 (1999).
49. Dykman, L. A. et al. Immunogenic properties of colloidal gold. Izv. Akad. Nauk Biol. 1, 86-91 (2004).
50. Diwan, M. et al. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J. Drug Target. 11, 495-507 (2003).
51. Cui, Z., Han, S. J., Vangasseri, D. P. & Huang, L. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol. Pharm. 2, 22-28 (2005).
52. Xiang, S. D. et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods 40, 1-9 (2006).
53. http://ncl.cancer.gov/120406.pdf
54. Tan, Y., Li, S., Pitt, B. R. & Huang, L. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum. Gene Ther. 10, 2153-2161 (1999).
55. Dileo, J. et al. Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol. Ther. 7, 640-648 (2003).
56. Whitmore, M. M., Li, S., Falo, L. Jr & Huang, L. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol. Immunother. 50, 503-514 (2001).
57. Diwan, M., Elamanchili, P., Cao, M. & Samuel, J. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Curr. Drug Deliv. 1, 405-412 (2004).
58. Tsao, N. et al. Inhibition of group A streptococcus infection by carboxyfullerene. Antimicrob. Agents Chemother. 45, 1788-1793 (2001).
59. Shvedova, A. A. et al. Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice. Am. J. Physiol. Lung C. 289, L698-L708 (2005).
60. Pulskamp, K., Diabate, S. & Krug, H. F. Carbon nanotubes show no sign of acute toxicity but induce intracellular reactive oxygen species in dependence on contaminants. Toxicol. Lett. 168, 58-74 (2007).
61. Muller, K. et al. Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro. Biomaterials 28, 1629-1642 (2007).
62. Shukla, R. et al. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir 21, 10644-10654 (2005).
63. van Zijverden, M. & Granum, B. Adjuvant activity of particulate pollutants in different mouse models. Toxicology 152, 69-77 (2000).
64. Lutsiak, M. E., Kwon, G. S. & Samuel, J. Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J. Pharm. Pharmacol. 58, 739-747 (2006).
65. Chong, C. S. et al. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J. Control. Release 102, 85-99 (2005).
66. Cui, Z. & Mumper, R. J. Coating of cationized protein on engineered nanoparticles results in enhanced immune responses. Int. J. Pharm. 238, 229-239 (2002).
67. Cui, Z. et al. Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles. Vaccine 22, 2631-2640 (2004).
68. de Kozak, Y. et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur. J. Immunol. 34, 3702-3712 (2004).
69. Balenga, N. A. et al. Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy. J. Biotechnol. 124, 602-614 (2006).
70. Rajananthanan, P., Attard, G. S., Sheikh, N. A. & Morrow, W. J. Novel aggregate structure adjuvants modulate lymphocyte proliferation and Th1 and Th2 cytokine profiles in ovalbumin immunized mice. Vaccine 18, 140-152 (1999).
71. Cui, Z., Hsu, C. H. & Mumper, R. J. Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev. Ind. Pharm. 29, 689-700 (2003).
72. Blander, J. M. & Medzhitov, R. On regulation of phagosome maturation and antigen presentation. Nat. Immunol. 7, 1029-1035 (2006).
73. Conner, S. D. & Schmid, S. L. Regulated portals of entry into the cell. Nature 422, 37-44 (2003).
74. Aderem, A. & Underhill, D. M. Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol. 17, 593-623 (1999).
75. Nagayama, S. et al. Fetuin mediates hepatic uptake of negatively charged nanoparticles via scavenger receptor. Int. J. Pharm. 329, 192-198 (2007).
76. Kim, T. H. et al. Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells. Mol. Cancer. Ther. 5, 1723-1732 (2006).
77. Cuna, M. et al. Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery. J. Nanosci. Nanotechnol. 6, 2887-2895 (2006).
78. Vonarbourg, A. et al. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J. Biomed. Mater. Res. A 78, 620-628 (2006).
79. von Zur Muhlen, C. et al. Superparamagnetic iron oxide binding and uptake as imaged by magnetic resonance is mediated by the integrin receptor Mac-1 (CD11b/CD18): Implications on imaging of atherosclerotic plaques. Atherosclerosis 193, 101-111 (2007).
80. Vonarbourg, A., Passirani, C., Saulnier, P. & Benoit, J. P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 27, 4356-4373 (2006).
81. Fang, C. et al. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur. J. Pharm. Sci. 27, 27-36 (2006).
82. Kwon, Y. J., Standley, S. M., Goh, S. L. & Frechet, J. M. Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles. J. Control. Release 105, 199-212 (2005).
83. Champion, J. A. & Mitragotri, S. Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA. 103, 4930-4934 (2006).
84. Shaunak, S. et al. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat. Biotechnol. 22, 977-984 (2004).
85. Cromer, J. R. et al. Functionalized dendrimers as endotoxin sponges. Bioorg. Med. Chem. Lett. 15, 1295-1298 (2005).
86. Chen, Y. W., Hwang, K. C., Yen, C. C. & Lai, Y. L. Fullerene derivatives protect against oxidative stress in RAW 264.7 cells and ischemia-reperfused lungs. Am. J. Physiol. Reg. I. 287, R21-R26 (2004).
87. John, A. E. et al. Discovery of a potent nanoparticle P-selectin antagonist with anti-inflammatory effects in allergic airway disease. Faseb J. 17, 2296-2298 (2003).
88. Dianzani, C. et al. Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion of human neutrophils to endothelial cells. Br. J. Pharmacol. 148, 648-656 (2006).
89. Higaki, M. et al. Treatment of experimental arthritis with poly(D, L-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate. Ann. Rheum. Dis. 64, 1132-1136 (2005).
90. Sundstrom, J. B. et al. Magnetic resonance imaging of activated proliferating rhesus macaque T cells labeled with superparamagnetic monocrystalline iron oxide nanoparticles. J. Acquir. Immune Defic. Syndr. 35, 9-21 (2004).
91. Putman, E., van der Laan, J. W. & van Loveren, H. Assessing immunotoxicity: guidelines. Fundam. Clin. Pharmacol. 17, 615-626 (2003).
92. Putman, E. et al. Assessment of the immunotoxic potential of human pharmaceuticals: a workshop report. Drug Inf. Journal 36, 417-427 (2002).
93. Snodin, D. J. Regulatory immunotoxicology: does the published evidence support mandatory nonclinical immune function screening in drug development? Regul. Toxicol. Pharmacol. 40, 336-355 (2004).
94. Haley, P. J. Guidelines on immunotoxicity testing of new chemical entities; consideration of a conundrum. Newsletter of the Society of Toxicology 3-5 (Fall, 2002).
95. Dean, J. H., Hincks, J. R. & Remandet, B. Immunotoxicology assessment in the pharmaceutical industry. Toxicol. Lett. 102-103, 247-255 (1998).
96. Patri, A. K., Dobrovolskaia, M. A., Stern, S. T. & McNeil, S. E. in Nanotechnology for Cancer Therapy 105-138 (CRC Press, Boca Raton, 2006).
97. http://www.fda.gov/nanotechnology/
98. http://ncl.cancer.gov
99. http://www.astm.org
100. http://www.iso.org
101. http://online.factsandcomparisons.com/index.aspx/
102. http://www.fda.gov/cder/foi/
103. Sharma, R. et al. Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data. J. Magn. Reson. Imaging 9, 291-294 (1999).
104. Enochs, W. S., Harsh, G., Hochberg, F. & Weissleder, R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J. Magn. Reson. Imaging 9, 228-232 (1999).
105. Paciotti, G. F. et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 11, 169-183 (2004).
106. Unger, E. C. et al. Nanoparticle drug delivery systems The Drug Delivery Companies Report 2001/02 61-63 (2001).
107. http://ncl.cancer.gov/120406.pdf
108. Gao, X. et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 22, 969-976 (2004).